Teleconferência de Resultados do 2º Trimestre de 2026 da Lantern Pharma (LTRN): Menor Prejuízo Operacional, LP-300 e Open Medicine AI
Teleconferência de resultados do 2º trimestre de 2026 da Lantern Pharma: o prejuízo operacional caiu 25%, para US$ 3,5 milhões, e o caixa ficou em US$ 7,4 milhões, enquanto o LP-300 e a Open Medicine AI avançaram.
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.